Glenmark Pharma Share Price in Focus; Revenue Up 0.6% in Q1 FY26 Results

Glenmark Pharmaceuticals released its financial results for the first quarter of FY26, reporting a modest revenue growth, stable profitability, and mixed performance across key geographies.

Consolidated Financial Performance

For Q1FY26, Glenmark recorded consolidated revenue of ₹32,644 million, a growth of 0.6% YoY compared to ₹32,442 million in Q1FY25. The company reported EBITDA of ₹5,805 million, compared to ₹5,607 million in the same quarter last year, resulting in an EBITDA margin of 17.8%.

The company’s Adjusted Profit After Tax (PAT) stood at ₹3,129 million, with an adjusted PAT margin of 9.6%, reflecting stability in earnings despite slower topline growth.

Commenting on the results, Glenn Saldanha, Chairman & Managing Director, Glenmark Pharmaceuticals Ltd, said, “In Q1FY26, our U.S. business delivered QoQ growth, driven by a combination of injectable and partnered products launches. Our Europe and Emerging markets businesses have recorded >25% CAGR and >10% CAGR respectively over the last three years, and we expect the region to deliver a double-digit growth from the second quarter onwards.”

He further added, “The recent IGI-AbbVie global licensing agreement for ISB 2001 is a strong validation of our innovation capabilities. We remain confident in our strategy to drive growth across our markets, while advancing our branded, specialty, and innovative products to deliver long-term value for our stakeholders.”

India Business

Sales from the formulation business in India reached ₹12,399 million, compared to ₹11,962 million in Q1FY25, registering a 3.7% YoY growth. The India business continues to be one of the strongest revenue contributors for Glenmark.

North America Business

Revenue from North America stood at ₹7,780 million, compared to ₹7,146 million in Q4FY25, reflecting 8.9% QoQ growth. The growth was driven by market share gains in injectable product launches and partnered products.

Emerging Markets

In emerging markets, including RCIS, LATAM, MEA, and APAC, Glenmark reported revenue of ₹5,721 million versus ₹5,708 million in Q1FY25, showing a marginal growth of 0.2% YoY. The company has reiterated its outlook of achieving double-digit growth on a constant currency basis in these markets.

Europe Business

Revenue from Europe stood at ₹6,678 million for Q1FY26, compared to ₹6,957 million in the previous year, reflecting a 4.0% YoY decline.

Glenmark Pharma Share Price Performance

On August 18, 2025, Glenmark Pharma share price (NSE: GLENMARK) opened at ₹2,009.90, down from its previous close of ₹2,044.60. At 9:23 AM, the share price of Glenmark Pharma was trading at ₹2,030.50, down by 0.69% on the NSE.

Also Read: Glenmark Signed Agreement with AbbVie for Cancer Drug!

Conclusion

Glenmark Pharmaceuticals delivered a steady Q1FY26 performance with marginal revenue growth and stable margins. While the India and North America businesses supported earnings, Europe saw a decline and emerging markets registered flat growth. The company remains focused on strengthening its core markets while targeting sustainable growth across geographies in the upcoming quarters.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.